Ketamine Nasal Spray: Spravato vs At-Home vs DIY

Not medical advice. Harm reduction information for people who have already decided to use. In an emergency, call your local emergency number. Some links are affiliate links; we may earn a commission at no cost to you.

Contents

Spravato is the one with the trials behind it
Telehealth ketamine is legal, growing, and thinly evidenced
A DIY spray buys you dose precision and nothing else
Where route matters, and where it stops
Sources

“Ketamine nasal spray” is three different products wearing one name. One is Spravato (esketamine), an FDA-approved prescription drug you can only receive inside a certified clinic under supervision. One is compounded ketamine prescribed by a telehealth service for use at home, legal but far less regulated. One is a homemade solution, ketamine powder dissolved in saline.

The evidence, legal status and supervision behind each are wildly different. What does not change between them is ketamine’s long-term risk profile, which tracks how much you take over months and years, not which bottle it came out of.

Spravato is the one with the trials behind it

Spravato is esketamine, the S-enantiomer of racemic ketamine, approved in the US in 2019 for treatment-resistant depression as an add-on to an oral antidepressant and in January 2025 as a standalone monotherapy. It is Schedule III and distributed under a Risk Evaluation and Mitigation Strategy: the clinic and pharmacy must be certified, the drug is never dispensed to patients to take home, and a provider must observe the patient for at least 2 hours after each dose for sedation, dissociation, respiratory changes and blood pressure spikes.

The evidence here is the strongest of the three categories, and it is randomised:

Popova’s 2019 phase 3 trial in American Journal of Psychiatry, 227 patients: esketamine plus a new antidepressant beat antidepressant plus placebo spray by 4.0 points on the MADRS depression scale at day 28. Dissociation, nausea, vertigo and dizziness appeared shortly after dosing and mostly resolved by 1.5 hours.
TRANSFORM-1 (Fedgchin 2019), 346 patients on fixed doses, missed its primary endpoint, with the 84 mg group failing to separate from placebo. Worth knowing, because this literature gets summarised as uniformly positive.
Daly’s 2019 randomised withdrawal study in JAMA Psychiatry, 297 stabilised patients: continuing esketamine cut relapse risk by 51% in stable remitters and 70% in stable responders.
ESCAPE-TRD (Reif 2023, NEJM), 676 patients head to head against extended-release quetiapine: week 8 remission was 27.1% versus 17.6%.
Janik’s 2025 monotherapy trial in JAMA Psychiatry, 378 patients: effect sizes of 0.48 at 56 mg and 0.63 at 84 mg at day 28. This is the trial behind the monotherapy approval.

Note what that is evidence for: supervised, twice-weekly dosing at 56 or 84 mg in a monitored clinic, in people with treatment-resistant depression. It is not evidence that ketamine nasal spray is safe in general.

Telehealth ketamine is legal, growing, and thinly evidenced

A separate market prescribes compounded racemic ketamine for home use. Most of it is sublingual troches or rapid-dissolve tablets rather than nasal spray, but nasal formulations exist. Compounded drugs are not FDA-approved products. There is no REMS, no certified clinic, no in-person monitoring, and the person is alone with a dissociative drug in their apartment.

The published outcomes are observational. Hull’s 2022 open-label series followed 1,247 patients through a commercial telehealth provider, with 62.8% reporting a 50% or greater PHQ-9 improvement and 32.6% remission. Mathai’s 2024 analysis of 11,441 patients taking four at-home doses over four weeks found adverse events in 3.0 to 4.8%, mostly neurologic or psychiatric, and the authors flag the absence of a control group and of fixed dosing.

The most current source is Mane’s 2026 systematic review in Australasian Psychiatry. Of 3,857 records screened, only three studies qualified, all from US commercial providers. All three were rated at critical overall risk of bias, and GRADE certainty for both effectiveness and safety was very low.

So the numbers look similar to clinic ketamine, but they are generated by the companies selling the treatment, with follow-up on a minority of patients. That is not the tier of evidence ESCAPE-TRD sits in. For contrast, Glue’s 2024 Nature Medicine trial of extended-release ketamine tablets was randomised and placebo-controlled, which is the design the at-home market mostly lacks.

The harm reduction concern is not whether at-home ketamine works. It is frequency. Supervised protocols are time-limited and counted. A refill in a drawer is not, and frequent repeated dosing is exactly the exposure pattern linked to bladder and cognitive harm.

A DIY spray buys you dose precision and nothing else

The third meaning is weighed ketamine powder dissolved into a measured volume of sterile saline and loaded into a spray bottle. No prescriber, no pharmacy, so everything rests on two numbers you set yourself: milligrams in, millilitres of solvent.

The genuine advantage is dose precision. A line is a guess. 500 mg dissolved in 5 mL gives 100 mg/mL, and a 0.1 mL actuator delivers 10 mg per spray. That matters with ketamine, where the gap between a light intranasal dose and a k-hole is often only 50 to 100 mg.

It does nothing about harm from the drug itself. Bladder damage, cognitive deficits and dependence all track cumulative exposure and frequency, not the device. See ketamine bladder damage and is ketamine addictive. A spray also tells you nothing about what the powder was, so test it first.

The rest of the detail has its own post: actuator volume, why evaporation makes a bottle stronger rather than weaker, the missing shelf-life data, and contamination. Read DIY ketamine nasal spray: dose math and safety.

Where route matters, and where it stops

Intranasal ketamine has a bioavailability of roughly 45 to 50%, with onset in 5 to 15 minutes. Route determines how fast and how hard a given milligram amount hits you, which is why a nasal dose is not interchangeable with an oral one. Full route comparisons are in our ketamine harm reduction guide.

Route does not determine long-term risk. Your bladder and your memory respond to total milligrams over months.

Three things apply to all three products:

Do not drive. Spravato patients are monitored for 2 hours and told not to drive until the next day after restful sleep. At-home use has nobody enforcing that.
Do not stack depressants. Ketamine with alcohol, benzodiazepines or opioids is the combination with documented deaths. Check specifics with our drug interaction checker.
Nobody alone in deep dissociation. The 2-hour observation window exists because dissociation, sedation and blood pressure spikes are the acute risks, and that window does not disappear when the setting changes.

If you use ketamine recreationally, a spray is a better dosing method than a line and no substitute for keeping frequency down. If you are weighing at-home telehealth ketamine, the honest summary is that its evidence is very low certainty and provider generated, while the strong trial data belongs to a different product delivered under supervision you will not be getting.

Sources